.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Federal Trade Commission
Dow
Citi
Mallinckrodt
US Army
Cerilliant
US Department of Justice
Teva

Generated: July 24, 2017

DrugPatentWatch Database Preview

Baxter Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has one hundred and sixty-seven approved drugs.

There are six US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are one hundred and fifteen patent family members on BAXTER HLTHCARE drugs in thirty-five countries.

Summary for Applicant: Baxter Hlthcare

Patents:6
Tradenames:280
Ingredients:95
NDAs:167
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
NEXTERONE
amiodarone hydrochloride
INJECTABLE;INJECTION022325-003Nov 16, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Baxter Hlthcare
CYTOXAN
cyclophosphamide
TABLET;ORAL012141-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION050648-003Dec 29, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
amino acids; dextrose
INJECTABLE;INJECTION019520-002Sep 23, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
HEPATASOL 8%
amino acids
INJECTABLE;INJECTION020360-001Apr 4, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
IFEX/MESNEX KIT
ifosfamide; mesna
INJECTABLE;INJECTION019763-003Oct 10, 1992► Subscribe► Subscribe
Baxter Hlthcare
ETHRANE
enflurane
LIQUID;INHALATION017087-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Baxter Hlthcare
IFEX/MESNEX KIT
ifosfamide; mesna
INJECTABLE;INJECTION019763-003Oct 10, 1992► Subscribe► Subscribe
Baxter Hlthcare
MESNEX
mesna
TABLET;ORAL020855-001Mar 21, 2002► Subscribe► Subscribe
Baxter Hlthcare
IFEX
ifosfamide
INJECTABLE;INJECTION019763-001Dec 30, 1988► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAXTER HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
esmolol hydrochloride
Injection10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags
BREVIBLOC
1/31/2014
desflurane
Inhalation99.90%
SUPRANE
9/11/2008

Non-Orange Book Patents for Baxter Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,886,789 Peritoneal dialysis and compositions for use therein► Subscribe
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
8,410,077Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Baxter Hlthcare Drugs

Country Document Number Estimated Expiration
Turkey200202557► Subscribe
Denmark2402008► Subscribe
Canada2771879► Subscribe
Australia3863085► Subscribe
TaiwanI277414► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
073Luxembourg► SubscribePRODUCT NAME: ACIDE BENZOIQUE 3-{6-{-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBONYL AMINO}-3-METHYLPYRIDIN-2-YL}, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN PRO-MEDICAMENT DE TYPE ESTER DE CELUI-CI; FIRST REGISTRATION DATE: 20151124
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
C/GB98/042United Kingdom► SubscribePRODUCT NAME: 2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3-METHYL-1-BUTYL)-AMINOCARBONYLMETHYL)-BENZOIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT AND/OR OPTIONALLY IN THE FORM OF AN ENANTIOMER, IN PARTICULAR (S)(+)-2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3; REGISTERED: UK EU/1/98/076/001 19980817; UK EU/1/98/076/002 19980817; UK EU/1/98/076/003 19980817; UK EU/1/98/076/004 19980817; UK EU/1/98/076/005 19980817; UK EU/1/98/076/006 19980817; UK EU/1/98/076/019 19980817; UK EU/1/98/076/020 19980817; UK EU/1/98/076/021 19980817; UK EU/1/98/076/013 19980817; UK EU/1/98/076/014 19980817; UK EU/1/98/076/015 19980817; UK EU/1/98/076/016 19980817; UK EU/1/98/076/017 19980817; UK EU/1/98/
C0076France► SubscribePRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
2016 00019Denmark► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCATBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOSYRE, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ELLER ET ESTERPRODRUG DERAF; REG. NO/DATE: EU/1/15/1059 20151124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Healthtrust
Federal Trade Commission
Medtronic
Teva
Chinese Patent Office
Queensland Health
Cipla
QuintilesIMS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot